SCHEMBL91338

SCHEMBL91338

CCc1c(F)ccc(F)c1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.37
TAAR1 Q96RJ0 1/20 0.34
TNF P01375 1/20 0.34
RIPK1 Q13546 1/20 0.34
HTR2A P28223 5/20 0.33
HTR2C P28335 5/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GAA P10253 1/20 0.32
TSHR P16473 1/20 0.32
HTR2B P41595 3/20 0.31
PKM P14618 1/20 0.31
CD38 P28907 1/20 0.31
CYP2A13 Q16696 1/20 0.31
FFAR4 Q5NUL3 1/20 0.31
ALDH1A1 P00352 1/20 0.30
ALOX15 P16050 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
BRD9 Q9H8M2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4120436 0.86 TAAR1 (0.36) P2RX7TAAR1MEN1KMT2ASMN1; SMN2
SCHEMBL2845042 0.86 TAAR1 (0.36) P2RX7TAAR1TNFRIPK1HTR2A
SCHEMBL24755342 0.84 CTRC (0.36) P2RX7TNFRIPK1HTR2AHTR2C
SCHEMBL20326196 0.84 CYP3A4 (0.39) MEN1KMT2ASMN1; SMN2GAATSHR
SCHEMBL9608978 0.84 P2RX7 (0.41) P2RX7TAAR1MEN1KMT2ASMN1; SMN2
SCHEMBL31152890 0.82 CYP1A2 (0.33) TAAR1
SCHEMBL16941869 0.79 HTR2A (0.42) HTR2AHTR2CMEN1KMT2ASMN1; SMN2
SCHEMBL12138245 0.78
SCHEMBL1363736 0.78 AR (0.44) HTR2AHTR2CHTR2BALDH1A1TDP1
SCHEMBL8415347 0.77 CYP1A2 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151007-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-05-18 US disclosed
US-20210220376-A1 ADDICTION TREATMENT OF AN ALCOHOL-CONSUMING PATIENT POPULATION AMYGDALA NEUROSCIENCES, INC. (US) 2021-07-22 US disclosed
US-20210145844-A1 COMBINATION THERAPY FOR NICOTINE ADDICTION AMYGDALA NEUROSCIENCES, INC. (US) 2021-05-20 US disclosed
US-9610299-B2 Compounds for the treatment of addiction GILEAD SCIENCES, INC. (US) 2017-04-04 US disclosed
US-9556168-B2 N-alkylated indole and indazole compounds as RORgammaT inhibitors and uses thereof MERCK SHARP & DOHME CORP. (US) 2017-01-31 US disclosed
US-9518000-B2 Bicyclo [2.2.1] acid GPR120 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2016-12-13 US disclosed
US-20160016880-A1 BICYCLO [2.2.1] ACID GPR120 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2016-01-21 US disclosed
US-20150210687-A1 N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF MERCK SHARP & DOHME LLC 2015-07-30 US disclosed
US-20150087632-A1 CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2015-03-26 US disclosed
US-8933085-B2 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors INCYTE CORPORATION (US) 2015-01-13 US disclosed
US-20120149681-A1 CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2012-06-14 US disclosed
US-20120135975-A1 Substituted Esters as Cannabinoid-1 Receptor Modulators MERCK & CO., INC. (US) 2012-05-31 US disclosed
US-8129538-B1 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-06 US disclosed
US-20080312435-A1 Imine Compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-18 US disclosed
US-7279484-B2 Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease AJINOMOTO CO., INC. (JP) 2007-10-09 US disclosed
US-7279484-B2 Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease AJINOMOTO CO., INC. (JP) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312435-A1 Imine Compound CNR1, CNR2, HRH4 P2RX7 225/4885TAAR1 122/4885TNF 1859/4885
US-20150210687-A1 N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF RORB, RORC, RORA P2RX7 1640/4885TAAR1 804/4885TNF 3592/4885
US-20210145844-A1 COMBINATION THERAPY FOR NICOTINE ADDICTION CHRNA2, ALDH2, ALDH1A1 P2RX7 1494/4885TAAR1 218/4885TNF 4636/4885
US-20160016880-A1 BICYCLO [2.2.1] ACID GPR120 MODULATORS GPR180, GPR88, GPBAR1 P2RX7 285/4885TAAR1 259/4885TNF 4694/4885
US-20120149681-A1 CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 P2RX7 953/4885TAAR1 3290/4885TNF 238/4885
US-20150087632-A1 CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS JAK2, JAK1, JAK3 P2RX7 939/4885TAAR1 3491/4885TNF 235/4885
US-20230151007-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG P2RX7 1177/4885TAAR1 3352/4885TNF 3039/4885
US-20210220376-A1 ADDICTION TREATMENT OF AN ALCOHOL-CONSUMING PATIENT POPULATION ADH1A, ADH1C, ALDH1A1 P2RX7 4691/4885TAAR1 78/4885TNF 4785/4885
US-20120135975-A1 Substituted Esters as Cannabinoid-1 Receptor Modulators CNR1, CNR2, FAAH P2RX7 1478/4885TAAR1 109/4885TNF 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.